Source: Recce Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) secures a US patent for its antibiotic product RECCE 327 and antiviral formulation RECCE 529
  • This is the company’s fourth of five patents to be granted, following China, Japan and Europe, with only Australia remaining
  • The US is considered the largest and most influential pharmaceutical market in the world, valued at US$339 billion (around A$461 billion)
  • On the market this morning, Recce was up 4.67 per cent and trading at $1.12 per share

Recce Pharmaceuticals (RCE) has been granted a US patent for its antibiotic product RECCE 327 and antiviral formulation RECCE 529.

This is the company’s fourth of five patent applications to be approved, following China, Japan and Europe, with only Australia remaining.

The US is considered the largest and most influential pharmaceutical market in the world, valued at US$339 billion (around A$461 billion).

Notably, the US market has developed and manufactured some of the world’s most innovative and best-selling drugs.

CEO James Graham is pleased with the anti-viral patent.

“Recce’s intellectual property portfolio continues to grow in line with our business strategy and the unprecedented global infectious disease crisis
before us,” Mr Graham said.

“We are thrilled to see that our Anti-viral patent was granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.”

Earlier this week, the company received a patent from the Chinese Patent Office.

On the market this morning, Recce was up 4.67 per cent and trading at $1.12 per share at 11:31 am AEST.

RCE by the numbers
More From The Market Herald
Genetic Technologies (ASX:GTG) - CEO, Simon Morriss

" Genetic Technologies (ASX:GTG) expands EasyDNA into Indian and European markets

Genetic Technologies (ASX:GTG) has embarked on a significant expansion of its recently acquired at-home DNA testing…
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…

" Antisense Therapeutics (ASX:ANP) dosing of muscular dystrophy drug on hold

Antisense Therapeutics (ASX:ANP) applies for partial clinical hold that limits dosing of its drug for muscular…